Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib plus GDC-0973 versus vemurafenib plus placebo in previously untreated BRAF V600-mutant advanced melanoma
NL-OMON44115Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of vemurafenib, cobimetinib and Placebo-COD Research Private Ltd, sponsored by Roche. Started Sep 2013; status: active, not recruiting.
02
Drugs
vemurafenibcobimetinibPlacebo-COD Research Private Ltd
Beyond the preview
Go deeper on NL-OMON44115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44115.